What it is
Insulin is a hormone made of 51 amino acids arranged in two chains. The A chain has 21 residues and the B chain has 30. Two disulfide bridges — bonds between sulfur atoms on cysteine residues — hold the chains together, and a third sits inside the A chain (UniProt P01308, read 2026-11-13).
The beta cells of the pancreas do not build it as two chains. They make one 110-residue precursor: a 24-residue signal piece, the B chain, a 31-residue connecting piece, and the A chain. The signal piece and the connecting piece are cut away. The connecting piece is C-peptide, which is released alongside insulin and measured as a marker of the body's own production.
Is it a peptide or a protein? At 51 residues it sits above the 40-residue line FDA uses, and every insulin application in FDA's database is a biologics licence. The peptide-versus-protein entry explains where that line comes from. Chemically it is a short pair of peptide chains, which is why older texts call it a peptide hormone.
| Property | Value | Source |
|---|---|---|
| A chain | 21 residues, GIVEQCCTSICSLYQLENYCN | UniProt P01308 |
| B chain | 30 residues, FVNQHLCGSHLVEALYLVCGERGFFYTPKT | UniProt P01308 |
| Disulfide bridges | 3 (2 between chains, 1 inside the A chain) | UniProt P01308 |
| Formula | C257H383N65O77S6 | PubChem CID 118984375; Humulin R label |
| Molecular weight | 5,808 | PubChem; label states 5.808 kDa |
The six sulfur atoms in the formula are the six cysteines that form the three bridges (our reading of the sequence: four cysteines in the A chain, two in the B chain).
What it does
The label for Humulin R, a regular human insulin, describes the mechanism in three statements. Insulin lowers blood glucose by stimulating glucose uptake, especially by skeletal muscle and fat. It inhibits glucose production by the liver. And it inhibits the breakdown of fat and protein while enhancing protein synthesis.
Its opposite number is glucagon, the hormone that raises blood glucose. The gut hormones that prompt the pancreas to release insulin after a meal are described under the incretin entry. Whether a GLP-1 medicine is an insulin is a separate question, answered on GLP1Ledger's page on GLP-1 and insulin.
What a label states
These figures come from one label — Humulin R U-100, the version dated 2023-10-31 in openFDA's label file. They describe that product and are reported here, not offered as guidance. Other insulins are engineered to act faster or longer and carry different figures.
| Measure | Figure on the Humulin R label |
|---|---|
| Indication | To improve glycaemic control in adult and paediatric patients with diabetes mellitus |
| Strength | 100 units per millilitre (U-100) |
| Onset under the skin | About 30 minutes (range 10 to 75 minutes) |
| Maximum effect | About 3 hours (range 20 minutes to 7 hours) |
| End of effect | About 8 hours (range 3 to 14 hours) |
| Half-life under the skin | About 1.5 hours (range 40 minutes to 7 hours) |
| Absorbed from under the skin | 48% to 89% |
| Contraindications | During episodes of hypoglycaemia; hypersensitivity to the product |
| Most common adverse reaction | Hypoglycaemia |
The label's warnings also name hypokalaemia (low blood potassium), severe allergic reactions, and mix-ups between insulin products. It states that the time course "may vary considerably in different individuals or within the same individual."
The approval record
FDA's drug database, in the openFDA copy dated 2026-11-10, held 37 applications with an insulin as an active ingredient when this entry read it on 2026-11-13. The count includes human insulin, engineered analogues, pre-mixed products and two combinations with a GLP-1 medicine. To check that the search worked, the same query for glucagon returned 12 applications.
| Date approved | Product | What it marked |
|---|---|---|
| 1982-10-28 | Humulin R, Humulin N (Lilly) | First recombinant human insulins in the database |
| 1991-06-25 | Novolin R (Novo Nordisk) | A second maker's human insulin |
| 1996-06-14 | Humalog (insulin lispro) | Earliest engineered analogue in the list |
| 2000-04-20 | Lantus (insulin glargine) | Earliest insulin glargine in the list |
| 2014-06-27 | Afrezza | Inhaled human insulin |
| 2021-07-28 | Semglee (insulin glargine-yfgn), BLA761201 | A second Semglee licence; the first is dated 2020-06-11 |
| 2026-03-26 | Awiqli (insulin icodec) | Among the four approvals dated 2026 |
| 2026-09-23 | Onswik (insulin efsitora alfa) | Newest in the list; label indication is adults with type 2 diabetes |
Two details from the same data. Six of the human-insulin applications — the Humulin and Novolin lines — carry the marketing status "Over-the-counter" as well as or instead of "Prescription". And the Onswik label says the product is not recommended in type 1 diabetes "due to increased risk of severe hypoglycemia."
A short history
- 1923: the Nobel Prize in Physiology or Medicine went to Frederick Banting and John Macleod "for the discovery of insulin" (Nobel Prize records).
- 1958: Frederick Sanger received the Nobel Prize in Chemistry "for his work on the structure of proteins, especially that of insulin."
- 1982: the first recombinant human insulins were approved in the United States.
What this entry does not cover
- Which insulin suits which person, and in what amount. Those are prescribing decisions, and the labels themselves say changes should be made under close medical supervision.
- Insulin prices and coverage.
- Use outside diabetes care. No approved label read for this entry describes one.
Where it stands
- Approved: yes, in many forms; 37 applications in FDA's database (2026-11-13).
- Classed as: a biologic in the United States.
- Research record: PubMed 170,547 title records, 7,795 of them tagged as randomised controlled trials; ClinicalTrials.gov 8,255 studies with an insulin as an intervention (2026-11-13).
Related reading
The growth factor named for its resemblance to insulin is described in the IGF-1 entry. Amylin, the second hormone released by the same pancreatic cells, and pramlintide, the medicine copied from amylin, sit beside insulin in diabetes care. For the wider family of gut and pancreas signals, see the GLP-1 entry.
